

AD-A169 376

ACTIONS OF INTERFERONS ON MACROPHAGES(U) TRUDEAU INST
INC SARANAC LAKE NY E A HAVELL ET AL. 20 JUN 86
N00014-83-C-0407


1/1

UNCLASSIFIED

F/G 6/15

NL





MICROCOPY

CHART

(U)

SECURITY CLASSIFI

AD-A169 376

DOCUMENTATION PAGE

1a. REPORT SECUR
(U)2a. SECURITY CLASSIFICATION AUTHORITY
NA2b. DECLASSIFICATION/DOWNGRADING SCHEDULE
NA4. PERFORMING ORGANIZATION REPORT NUMBER(S)
Trudeau Institute, Inc.6a. NAME OF PERFORMING ORGANIZATION
Trudeau Institute, Inc.6b. OFFICE SYMBOL
(If applicable)
NA6c. ADDRESS (City, State, and ZIP Code)
P.O. Box 59
Saranac Lake, NY
129838a. NAME OF FUNDING/SPONSORING
ORGANIZATION
Office of Naval Research8b. OFFICE SYMBOL
(If applicable)
ONR8c. ADDRESS (City, State, and ZIP Code)
800 N. Quincy St.
Arlington, VA
22217-50001b. RESTRICTIVE MARKINGS
NA3. DISTRIBUTION/AVAILABILITY OF REPORT
Distribution Unlimited5. MONITORING ORGANIZATION REPORT NUMBER(S)
NA7a. NAME OF MONITORING ORGANIZATION
Office of Naval Research7b. ADDRESS (City, State, and ZIP Code)
800 N. Quincy St.
Arlington, VA 22217-50009. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER
N00014-83-C-0407

10. SOURCE OF FUNDING NUMBERS

PROGRAM
ELEMENT NO.
61153NPROJECT
NO.
RRO4108TASK
NO.
NR 666-020WORK UNIT
ACCESSION NO

11. TITLE (Include Security Classification)

Actions of Interferons on Macrophages

12. PERSONAL AUTHOR(S) Havell, Edward, A.; Vogel, Stephanie, N.; Spitalny, George, L.

13a. TYPE OF REPORT
Final13b. TIME COVERED
FROM 5/85 TO 6/8614. DATE OF REPORT (Year, Month, Day)
86, June, 2015. PAGE COUNT
7

16. SUPPLEMENTARY NOTATION

17. COSATI CODES

FIELD	GROUP	SUB-GROUP
08		

18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)

Macrophages, fibroblasts, murine gamma interferon (MuIFN γ),
monoclonal antibody (Mab), Fc receptor, Ia antigen,
Listeria monocytogenes

19. ABSTRACT (Continue on reverse if necessary and identify by block number)

DTIC FILE COPY

A rat anti-murine gamma interferon (MuIFN γ) neutralizing monoclonal antibody (Mab) was used to investigate the effect of MuIFN γ on the development of antiviral resistance, Fc receptor expression, and Ia antigen in macrophages. These studies were carried out in cultures of C3H/HeJ peritoneal macrophage cultures in order to determine: 1) whether MuIFN γ can influence the expression of the above parameters, 2) the relative quantity of MuIFN γ required to mediate each effect, and 3) the amount of anti-MuIFN γ Mab required to neutralize each MuIFN γ -mediated effect. The results of these studies established that macrophages are at least as sensitive to the antiviral action of MuIFN γ as other cell types tested, however,

20. DISTRIBUTION/AVAILABILITY OF ABSTRACT

☒ UNCLASSIFIED/UNLIMITED ☐ SAME AS RPT. ☐ DTIC USERS
27a. NAME OF RESPONSIBLE INDIVIDUAL
Dr. J.A. Majde21. ABSTRACT SECURITY CLASSIFICATION
(U)22b. TELEPHONE (Include Area Code)
202-696-405522c. OFFICE SYMBOL
ONR

19. Abstract cont.

Substantially more MAb was needed to neutralize MuIFN γ -mediated antiviral activity in macrophages. It was also found that 10-15 times more MAb was required to inhibit MuIFN γ -induced Fc receptor expression than was required for Ia antigen expression. These latter findings confirm and extend previous observations, which indicate the MuIFN γ induction of enhanced expression of these two macrophage membrane differentiation markers occurs through distinct mechanisms.

During the course of a sublethal Listeria monocytogenes infection, all three IFN classes (α , β , γ) are produced by the host. In addition to their antiviral activities, IFNs can mediate a variety of different effects which could conceivably have a bearing on the expression of host nonspecific and/or specific resistance mechanisms. Interferons have been reported to suppress the intracellular multiplication of a variety of nonviral intracellular organisms. Since Listeria is a facultative intracellular bacterium, capable of multiplying in both professional and non-professional phagocytic cells of infected organs, a model of intracellular Listeria infection of nonprofessional phagocytes (fibroblasts) was developed. It was found that IFN α/β and IFN γ both inhibit intracellular Listeria proliferation. Moreover, during intracellular Listeria proliferation, infected fibroblasts produce IFN α/β . Thus, in vivo, Listeria-infected nonphagocytic cells, such as hepatocytes, may be an important source of IFN α/β which through its inhibitory action on intracellular Listeria multiplication, may serve to restrict the magnitude of infection faced by the host.

Accession For	
NTIS CRA&I	☒
DTIC TAB	☐
Unannounced	☐
Justification	
By	
Distribution /	
Availability Codes	
Dist	Avail. and/or Special
A-1	



FINAL REPORT
N00014-83-C-0407
Actions of Interferons on Macrophages

I. MuIFN γ -Mediated Effects on Macrophages

Previously, we reported on the generation of a rat:mouse hybridoma (R4-6A2) which secretes rat anti-MuIFN γ neutralizing monoclonal antibody (MAB). This MAB was used to establish that MuIFN γ was the factor present in crude lymphokine preparations which was responsible for priming macrophages for enhanced tumoricidal activity (1). Since this finding, studies have been undertaken to both produce and purify sufficient quantities of the MAB to further study MuIFN γ -mediated effects (2).

The ability of the R4-6A2 anti-MuIFN γ MAB to neutralize several different activities of MuIFN γ was recently examined (3). The MAB was found to neutralize the ability of MuIFN γ to inhibit the growth (anti-proliferative activity) of fibroblast cells in culture. The ability of MuIFN γ to render cells of a heterologous species (rat) resistant to viral replication was also neutralized by this MAB. The MAB neutralizing titers for MuIFN γ antiviral activities, on both homologous (murine L929B fibroblast) and heterologous (rat fibroblast) cells, were inversely proportional to the antiviral activity titers on each cell type (2). This linear relationship between the MAB neutralizing titer and the quantity of MuIFN γ (antiviral activity) neutralized was not observed in the earlier studies on MAB neutralization of MuIFN γ -induced macrophage tumoricidal activity (1). However, the quantity of MAB required to eliminate the macrophage activating potential of MuIFN γ , as assessed by the enhanced ability of these cells to destroy tumor targets, was in excess of 20-100 times that required to abolish antiviral activity on fibroblasts.

Macrophages are thought to be very sensitive to MuIFN γ -mediated effects. One possible explanation as to why more MAB is required to neutralize MuIFN γ -induced effects in macrophages, is that macrophages may be relatively more sensitive to MuIFN γ than fibroblasts. Therefore, more MAB would be needed to achieve a higher degree of neutralization of MuIFN γ -mediated effects in macrophages, than is required in less sensitive cell types. Studies were undertaken in collaboration with Dr. Stephanie Vogel (Uniformed Services University, Bethesda, MD) to examine the quantity of MuIFN γ required to evoke antiviral resistance, as well as the enhanced expression of certain macrophage membrane markers. Thus, based on the quantity of MuIFN γ needed to elicit macrophage resistance to virus infection, it would be possible to relate the degree of MAB neutralization achieved to the quantity of antigen (MuIFN γ antiviral activity) required to protect cells of varying sensitivities to virus infection, and to other MuIFN γ -mediated effects in macrophages.

In order to analyze MuIFN γ antiviral activity in macrophages, cultures of peritoneal macrophages were established from C3H/HeJ mice. These cells proved permissive for vesicular stomatitis virus (VSV) replication and were used to study the antiviral action of MuIFN γ by means of both viral cytopathic and virus yield assays. Based on relative antiviral activity in fibroblast cultures, it was observed that as little as 0.5 MuIFN γ laboratory reference units induced a state of antiviral resistance in macrophages, and that these phagocytic cells exhibited approximately the same sensitivity to the antiviral activity of MuIFN γ against VSV challenge as fibroblasts. Moreover, the quantity of MAb required to neutralize the antiviral activity of MuIFN γ half maximally, was 20-100 times greater than that required for MuIFN γ antiviral activity on fibroblasts (3). This finding was similar to that observed for MuIFN γ -induced macrophage activation (1). These results suggest that since macrophages and fibroblasts exhibit similar sensitivities to MuIFN γ -induced antiviral resistance, other reasons must account for why considerably more neutralizing MAb is needed to neutralize MuIFN γ -mediated effects in macrophages, than is required in cultures of fibroblasts.

MuIFN γ -induced enhanced expression of macrophage FcR and Ia antigen expression was also examined in cultures of C3H/HeJ macrophages (3). It was found that both recombinant or natural MuIFN γ preparations elicited increased FcR and Ia antigen expression over approximately the same concentration ranges and periods of time. As with MuIFN γ -induced antiviral resistance in both macrophages and fibroblasts, 5.0 units of MuIFN γ resulted in maximum FcR and Ia expression. The capacity of the R4-6A2 anti-MuIFN γ MAb to neutralize the ability of MuIFN γ to induce these macrophage differentiation markers was assessed. To be consistent with the definition of the neutralization titer for antiviral activity, the highest dilution of MAb that reduced the FcR- or Ia-inducing effects of 5.0 units of MuIFN γ by 50% was chosen as the endpoint in the neutralization assay. The neutralization titer of the MAb to reduce MuIFN γ induced FcR half maximally was 10^3 . In contrast, the neutralizing titer of the MAb for MuIFN γ -induced Ia expression was $1-5 \times 10^4$. Thus, significantly less MAb was required to inhibit MuIFN γ -induced Ia expression than was required for either MuIFN γ -induced antiviral resistance or FcR expression.

II. Antimicrobial Functions of Interferons.

The response of mice to the bacterium, Listeria monocytogenes, offers an excellent model for studying the possible roles of interferons (IFNs) in preimmunity resistance and acquired specific resistance to a facultative intracellular pathogen. Results of studies carried out in this laboratory have established that during a sublethal immunizing Listeria infection all three classes of IFN are produced. Moreover, the infected host acquires an augmented capacity to produce all three IFNs in response to appropriate IFN-inducing agents (4). In view of these findings, and the reported activities of IFNs which could influence the course of a bacteria infection; such as (a) suppressing proliferation of intracellular bacteria, (b)

enhancing the bactericidal activities of macrophages, and (c) possible immunomodulatory activities, it is conceivable that IFNs produced during listeriosis may function in resistance. A goal of our research is to determine the functions of each IFN in resistance to a nonviral infectious disease, using murine listeriosis as an experimental model.

The following studies have either been performed, or are currently underway to establish whether an IFN functions in resistance to Listeria, and if so, its role in either specific and/or nonspecific resistance.

Examination of a possible role of IFNs in nonspecific resistance to Listeria. In vitro, IFNs have been found to suppress the intracellular proliferation of certain bacteria. Histological examination of Listeria-infected livers has established that this bacterium proliferates in both professional and nonprofessional phagocytic cells. Therefore, if IFNs inhibit intracellular Listeria multiplication in vivo, such an action would constitute an important aspect in nonspecific resistance to this pathogen. An in vitro model of Listeria infection of nonprofessional phagocytes was developed during the past year in order to investigate possible effects of each IFN class on intracellular multiplication of this gram-positive facultative bacterium. This model uses murine embryo fibroblasts and the aminoglycoside antibiotic, gentamicin sulfate, at a concentration that is listericidal for extracellular, but not intracellular bacteria. The following is a list of our findings:

1. During exponential growth, the extracellular doubling time of Listeria is 25 minutes, whereas the intracellular doubling time is estimated to be 2.5 hr (Fig. 1). Quantitation of cell-associated Listeria is performed by lysing fibroblasts with 0.05% deoxycholate and then plating the lysate on agar.

2. During the intracellular proliferation of Listeria, infected fibroblasts produce substantial quantities of IFN (Fig 2). This Listeria-induced IFN has been characterized as to certain physicochemical properties and antigenicity (Table 1), and has been found to be indistinguishable from virus-induced IFN α/β (5). Thus, one potential source of serum IFN α/β detected during the peak of Listeria growth in the liver and spleen may be infected nonprofessional phagocytes, such as parenchymal cells.

3. Microscopic examination of Listeria-infected fibroblast cultures reveals that, following the initial infection procedure, approximately 1% of the fibroblasts are associated with Listeria. Internalized bacteria proliferate and eventually occupy the entire cytoplasm, after which the host cell is destroyed and bacteria are released into the culture medium. Cells that are both contiguous and distant to the infectious focus become infected. Subsequent cycles of this infectious process results in destruction of the fibroblast monolayer in two days.

4. The use of semi-solid agar overlays, to prevent the random dispersal of extracellular Listeria from destroyed cells, has allowed the microscopic observation of cell to cell spread of infection. The agar overlay permits only the radial spread of infection. The following are our observations on cell to cell spread of intracellular Listeria:

a) All cells adjacent to an infected fibroblast become infected.

b) Spread of Listeria is not contingent on the disruption of the infected cell. This can be suggested because even towards the center of an advanced focus of infection, many heavily infected cells possess intact plasma membranes.

c) In more recently infected cells, towards the periphery of the infectious focus, Listeria appears to be within phagocytic vacuoles. This would suggest that intercellular spread of Listeria may occur through phagocytosis.

d) In contrast to the total destruction of the infected monolayer maintained in fluid medium for 48 hrs, the infected cultures overlaid with agar for 48 hrs possess the same number of infectious foci as observed 24 hrs earlier, but each focus was larger and contained more dead cells. The progressive nature of Listeria infection of fibroblasts maintained under agar eventually became macroscopically evident as discreet plaques in the monolayer.


5. $\text{IFN}\alpha/\beta$ and $\text{IFN}\gamma$ suppress intracellular Listeria infection of fibroblasts. However, $\text{IFN}\gamma$ appears to differ from $\text{IFN}\alpha/\beta$ in its anti-Listeria effect. This conclusion is based on results obtained with the Listeria plaquing technique mentioned above to assess the effect of IFNs on intracellular Listeria infection. Based on what has been reported for IFN-mediated effects that could conceivably inhibit intracellular multiplication of parasites, there are four potential sites where IFNs could affect inhibitory actions. These are: 1) initial association of Listeria with the cytoplasmic membrane; 2) the internalization process; 3) intracellular multiplication; and 4) the subsequent infection of neighboring fibroblasts. It has been found that if fibroblasts are treated with $\text{MuIFN}\gamma$ prior to infection with Listeria, the resulting plaque number is greatly reduced. This $\text{MuIFN}\gamma$ -mediated effect is dose dependent and requires 12-18 hrs to develop. Similar treatment of fibroblasts with $\text{MuIFN}\alpha/\beta$ has little, or no effect on bacterial plaque numbers. However, plaque size is reduced in the $\text{MuIFN}\alpha/\beta$ treated fibroblasts. These different inhibitory effects of the IFNs would suggest that $\text{MuIFN}\gamma$ inhibits an early event in the infectious process, whereas $\text{MuIFN}\alpha/\beta$ may induce a cellular event which inhibits intracellular Listeria multiplication. If indeed, these MuIFNs differ in their inhibitory effects on the intracellular Listeria infectious process, then their combined actions might very well result in a synergistic anti-Listeria effect.

References

1. Spitalny, G.L. and Havell, E.A. (1984). Monoclonal antibody to $\text{MuIFN}\gamma$ inhibits lymphokine-induced antiviral and macrophage tumoricidal activities. J. Exp. Med. 159:1560-1565.


2. Havell, E.A. (1986). Purification and further characterization of an anti-MuIFN γ monoclonal antibody. (Submitted: J. Interferon Res.)
3. Vogel, S.N., Havell, E.A., and Spitalny, G.L. (1986). Monoclonal antibody-mediated inhibition of interferon- γ -induced macrophage antiviral resistance and surface antigen expression. J. Immunol. 136:2917-2923.
4. Havell, E.A. (1986). Augmented induction of Interferons during Listeria monocytogenes infection. J. Infectious Dis. 153:960-969.
5. Havell, E.A. (1986). Synthesis and secretion of interferon by murine fibroblasts in response to intracellular Listeria monocytogenes. (Submitted: Infect. Immun.).

Figure 1



Intracellular and extracellular multiplication of *Listeria monocytogenes*. *Listeria* growth in EMEM containing no antibiotics (■); EMEM containing gentamicin sulfate (0.25 $\mu\text{g}/\text{ml}$) (▲); or in murine embryo fibroblast monolayers incubated with EMEM containing 0.25 $\mu\text{g}/\text{ml}$ of gentamicin sulfate (●).

Figure 2



Listeria monocytogenes-induced IFN synthesis in murine embryo fibroblasts. Interferon titers (units/ml) in murine embryo fibroblast culture media at various intervals follow the initial 2 hr Listeria adsorption period with ratios of infection of 10 Listeria/cell (solid bars); 0.5 Listeria/cell (dotted bars); or no Listeria (striped bars).

DISTRIBUTION LIST

Immunological Defense Program

Annual, Final and Technical Reports (one copy each except as noted)

Dr. John D. Clements
Department of Microbiology
and Immunology
Tulane University
1430 Tulane Avenue
New Orleans, LA 70112

Francis A. Ennis, M.D.
Department of Medicine
University of Massachusetts
Medical School
55 Lake Avenue
Worcester, MA 01605

Dr. Edward A. Havell
Trudeau Institute
P.O. Box 59
Saranac Lake, NY 12983

Dr. Arthur G. Johnson
Department of Medical
Microbiology and Immunology
University of Minnesota
School of Medicine
2205 East 5th Street
Duluth, MN 55812

Dr. Matthew J. Kluger
Department of Physiology
University of Michigan Med. School
7620 Medical Science II Building
Ann Arbor, MI 48109

Dr. Roger M. Loria
Department of Microbiology
and Immunology
Virginia Commonwealth University
Box 678, MCV Station
Richmond, VA 23298-0001

Dr. Ernest D. Marquez
Bioassay Systems Corporation
225 Wildwood Avenue
Woburn, MA 01801

Dr. Robert I. Mishell
Department of Microbiology
and Immunology
University of California, Berkeley
Berkeley, CA 94720

James J. Mond, M.D.
Department of Medicine
Uniformed Services University
of the Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20814

Dr. Page S. Morahan
Department of Microbiology
Medical College of Pennsylvania
3300 Henry Avenue
Philadelphia, PA 19129

David A. Stevens, M.D.
Department of Medicine
Santa Clara Valley Medical Center
Stanford University
751 S. Bascom Avenue
San Jose, CA 95128

Dr. Barnet M. Sultzer
Department of Microbiology
and Immunology
Downstate Medical Center
450 Clarkson Avenue

G. Jeanette Thorbecke, M.D.
Department of Pathology
New York University
School of Medicine
550 First Avenue
New York, NY 10016

Dr. Alvin L. Winters
Department of Microbiology
University of Alabama
University, AL 35486

Annual, Final and Technical Reports (one copy each except as noted)

Dr. Jeannine A. Majde, Code 441CB
Scientific Officer, Immunology Program
Office of Naval Research
800 N. Quincy Street
Arlington, VA 22217

Administrator (2 copies) (Enclose DTIC Form 50)
Defense Technical Information Center
Building 5, Cameron Station
Alexandria, VA 22314

Annual and Final Reports Only (one copy each)

Commanding Officer
Naval Medical Command
Washington, DC 20372

Commanding Officer
Naval Medical Research & Development Command
National Naval Medical Center
Bethesda, MD 20814

Director, Infectious Diseases Program Center
Naval Medical Research Institute
National Naval Medical Center
Bethesda, MD 20814

Commander
Chemical and Biological Sciences Division
Army Research Office, P.O. Box 12211
Research Triangle Park, NC 27709

Commander
U.S. Army Research and Development Command
Attn: SGRD-PLA
Fort Detrick
Frederick, MD 21701

Commander
USAMRIID
Fort Detrick
Frederick, MD 21701

Directorate of Life Sciences
Air Force Office of Scientific Research
Bolling Air Force Base
Washington, DC 20332

Administrative Contracting Officer
ONR Resident Representative
(address varies - obtain from Business Office)

Final and Technical Reports Only

Director, Naval Research Laboratory (6 copies)
Attn: Technical Information Division, Code 2627
Washington, DC 20375

END

DTIC

7-86